Positron-emission tomography (PET) imaging with 89Zr-atezolizumab (anti-PD-L1) in NSCLC, bladder and triple-negative breast cancer showed that tracer uptake was heterogenous and corresponded to PD-L1 and IFN-γ signaling levels at sites, appearing to be a strong predictor of atezolizumab response [240]. The gene discussed is CD274; the disease is triple-negative breast carcinoma.